Synergy CHC Corp.
SNYR evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNYR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNYR
Synergy CHC Corp. (SNYR) is a consumer healthcare company that markets and distributes branded over-the-counter products, currently navigating liquidity challenges with a negative equity position and ongoing debt restructuring.
Key risk: Negative equity and high debt
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Synergy CHC Corp. (SNYR) is a consumer healthcare company that markets and distributes branded over-the-counter products, currently navigating liquidity challenges with a negative equity position and ongoing debt restructuring.
- Cash and equivalents of $0.4M as of 2026-03-31 [sec].
- Total revenue of $5.5M and net loss of -$2.6M for the period ended 2026-03-31 [sec].
- Shareholders' equity of -$23.1M and total debt of $27.7M as of 2026-03-31 [sec].
- Working capital surplus of $1,778,308 as of 2026-04-01 [sec_mda].
- Raised $3.7M through common stock sales in 2025 and restructured debt agreements extending into 2029 [sec_mda].
What works
- Working capital surplus of $1,778,308 as of 2026-04-01 provides near-term liquidity [sec_mda].
- Debt restructuring in 2025 extended terms into 2029, and a second amendment in 2026 adjusted covenants and payment terms [sec_mda].
- Established an at-the-market equity offering program to raise capital subject to market conditions [sec_mda].
What to weigh
- Negative shareholders' equity of -$23.1M and total debt of $27.7M as of 2026-03-31 indicate a highly leveraged balance sheet [sec].
- Net loss of -$2.6M for the period ended 2026-03-31 and a decrease in net revenue of $7,943,390 at December 31, 2024 [sec_mda].
- Laid off 13 employees to reduce overhead, signaling cost pressures [sec_mda].
- Historical working capital deficits and reliance on related-party loans and equity sales to meet obligations [sec_mda].
From the filings
Quoted directly from source documents.
Working capital surplus of $1,778,308 as of 2026-04-01
“Company had a working capital surplus of $1,778,308.”
SEC MD&A · April 1, 2026
Debt restructuring extended terms into 2029
“The Company has restructured its debt agreements in 2025 which extends the terms into 2029.”
SEC MD&A · April 1, 2026
Laid off 13 employees to right-size overhead
“The Company has laid off 13 employees in order to right size its overhead expenses.”
SEC MD&A · April 1, 2026
Risks & what to watch (4)›
Key risks
- Negative equity and high debt — Shareholders' equity of -$23.1M and total debt of $27.7M as of 2026-03-31 [sec].
- Revenue decline and net losses — Net loss of -$2.6M for period ended 2026-03-31 and revenue decrease of $7.9M at Dec 31, 2024 [sec_mda].
- Going concern uncertainty — Historical working capital deficits and reliance on related-party loans and equity sales to meet obligations [sec_mda].
- Competitive pressure — Ability to compete against competitors with significantly greater financial, technical and marketing resources [sec].
What to watch
- Ability to generate positive cash flow from operations and reduce net losses [sec_mda].
- Progress on debt restructuring and covenant compliance under the 2026 amendment [sec_mda].
- Success of the ATM equity offering program in raising additional capital [sec_mda].
- Impact of employee layoffs on operational efficiency and product development [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run Synergy CHC Corp. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Synergy CHC Corp. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.2 months
OCF -$2M · Net income -$3M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
9
Total value held
$2.2M
| Holder | Shares | Value |
|---|---|---|
| gratia capital, llc | 550,000 | $710K |
| heartland advisors inc | 550,000 | $710K |
| sanders morris harris llc | 415,452 | $536K |
| vanguard capital management llc | 179,540 | $232K |
| vanguard fiduciary trust co | 23,149 | $30K |
| geode capital management, llc | 21,398 | $28K |
| ubs group ag | 900 | $1K |
| clearstead advisors, llc | 109 | $141 |
| citigroup inc | 1 | $1 |
Short Interest
as of May 22, 2026- % of float
- 2.8%
- Days to cover
- 0.1
- Shares short
- 229,140
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNYR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Synergy CHC Corp.?
Synergy CHC Corp. (SNYR) is a consumer healthcare company that markets and distributes branded over-the-counter products, currently navigating liquidity challenges with a negative equity position and ongoing debt restructuring.
Who is the CEO of Synergy CHC Corp.?
Mr. Jack Ross is the chief executive officer of Synergy CHC Corp. (SNYR).
Where is Synergy CHC Corp. headquartered?
Synergy CHC Corp. (SNYR) is headquartered in Windham, ME, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.